CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cellectar Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cellectar Biosciences Inc
100 Campus Dr
Phone: (608) 441-8120p:608 441-8120 FLORHAM PARK, NJ  07932-1020  United States Ticker: CLRBCLRB

Business Summary
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Stephen A.Hill 63 9/19/2007 9/19/2007
President, Chief Executive Officer, Director James V.Caruso 58 6/15/2015 6/15/2015
Chief Financial Officer DovElefant 9/10/2019 9/10/2019
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cellectar, LLC 545 Science Drive Madison WI United States

Business Names
Business Name
Cellectar, Inc.
CLRB

General Information
Number of Employees: 15 (As of 12/31/2016)
Outstanding Shares: 9,386,703 (As of 9/30/2019)
Shareholders: 336
Stock Exchange: NASD
Federal Tax Id: 043321804
Fax Number: (608) 441-8121


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 16, 2019